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ABSTRACT
The D1 dopamine receptor (D1R) has been proposed to form
a hetero-oligomer with the D2 dopamine receptor (D2R), which in
turn results in a complex that couples to phospholipase C–
mediated intracellular calcium release. We have sought to
elucidate the pharmacology and mechanism of action of this
putative signaling pathway. Dopamine dose-response curves
assaying intracellular calcium mobilization in cells heterolo-
gously expressing the D1 and D2 subtypes, either alone or in
combination, and using subtype selective ligands revealed that
concurrent stimulation is required for coupling. Surprisingly,
characterization of a putative D1-D2 heteromer-selective ligand,
6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-
benzazepine-7,8-diol (SKF83959), found no stimulation of cal-
cium release, but it did find a broad range of cross-reactivity with
other G protein–coupled receptors. In contrast, SKF83959 appeared
to be an antagonist of calcium mobilization. Overexpression of
Gqa with the D1 and D2 dopamine receptors enhanced the
dopamine-stimulated calcium response. However, this was also
observed in cells expressing Gqa with only the D1R. Inactivation
of Gi or Gs with pertussis or cholera toxin, respectively, largely,
but not entirely, reduced the calcium response in D1R and D2R
cotransfected cells. Moreover, sequestration of Gbg subunits
through overexpression of G protein receptor kinase 2 mutants
either completely or largely eliminated dopamine-stimulated
calcium mobilization. Our data suggest that the mechanism of
D1R/D2R–mediated calcium signaling involves more than
receptor-mediated Gq protein activation, may largely involve
downstream signaling pathways, and may not be completely
heteromer-specific. In addition, SKF83959 may not exhibit
selective activation of D1-D2 heteromers, and its significant
cross-reactivity to other receptors warrants careful interpre-
tation of its use in vivo.
Introduction
Dopamine is a neurotransmitter that functions in the
central nervous system to regulate neural processes that
include motor control, cognition, and memory. Dysregulation
of the dopamine (DA) system is associated with neurologic
disorders such as Parkinson disease, schizophrenia, addic-
tion, and attention deficit hyperactivity disorder. Five DA
receptor (DAR) genes exist in mammals, each of which
encodes a DAR subtype (D1R–D5R); these genes are grouped
by structure and function into the D1-like (D1R and D5R) and
D2-like (D2R, D3R, and D4R) DAR families. The D1-like
receptors couple to the Gs/olf proteins to activate adenylyl
cyclase–mediated formation of cAMP, whereas the D2-like
receptors couple to the Gi/o proteins to inhibit adenylyl cyclase
(Sibley and Monsma, 1992; Missale et al., 1998). Several
studies, however, have proposed DAR-mediated signaling
pathways that do not involve activation of either Gi/o or Gs/olf
proteins.
The first evidence for alternate signaling pathways came
from multiple studies reporting “D1-like” receptor stim-
ulation of intracellular calcium mobilization, which was
suggested to be a result of Gq-mediated activation of
phospholipase C (PLC) (Mahan et al., 1990; Undie and
Friedman, 1990; Wang et al., 1995; Pacheco and Jope,
1997). Subsequently, it was shown that in vitro cell cultures
coexpressing the D1R and D2R could couple to intracellu-
lar calcium mobilization through the Gq-PLC-diacylglycerol
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pathway (Lee et al., 2004; Rashid et al., 2007a). This calcium
response required both coexpression and coactivation of both
receptor subtypes. This led to the proposal of a “noncanonical”
mechanism for DAR-mediated signaling wherein the D1R
forms a heteromeric complex with the D2R and induces PLC-
mediated intracellular calcium mobilization (Lee et al., 2004;
Rashid et al., 2007b; Hasbi et al., 2011). The precise mechanism
for this type of signaling and its prevalence in vivo, however,
remain unclear.
In vivo, there is evidence both for (Surmeier et al., 1992,
1996; Lester et al., 1993; Ariano et al., 1997; Aizman et al.,
2000; Lee et al., 2004) and against (Gerfen et al., 1990; Le
Moine et al., 1991; Hersch et al., 1995; Le Moine and Bloch,
1995; Bertran-Gonzalez et al., 2008) the existence of neural
cells coexpressing both D1R and D2R. Interestingly, some
neurons that appear to coexpress D1R and D2R have neuronal
projections that express only D1R or only D2R (Lee et al.,
2004). This finding, along with the different methods of
detection and visualization, may partially explain the in-
congruent reports of D1R and D2R colocalization. However,
several recent studies using confocal FRET techniques argue
for direct demonstration of the existence of D1-D2 heteromers
in 10–20% of the cell bodies and presynaptic terminals of
medium spiny neurons within the nucleus accumbens (Hasbi
et al., 2009; Perreault et al., 2011, 2012a), and the two DARs
have been shown to cointernalize after selective activation of
either receptor (O’Dowd et al., 2005; So et al., 2005).
Interestingly, several agonists of the benzazepine family
seem to exhibit differential effects on the D1R monomer
compared with the proposed D1-D2 heteromer (Rashid et al.,
2007b). One such compound, 6-chloro-2,3,4,5-tetrahydro-1-
(3-methylphenyl)-3-(2-propenyl)-1H-3-benzazepine-7,8-diol
(SKF83822), has been proposed to selectively activate D1R-
mediated cAMP production but have no effect on calcium
mobilization (Rashid et al., 2007a,b). In contrast, another
benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-
methylphenyl)-1H-3-benzazepine-7,8-diol (SKF83959), has been
proposed to selectively activate the heteromer-mediated calcium
release and have no effect on cAMP production (Rashid et al.,
2007a,b; Hasbi et al., 2011). More recent studies have used this
finding to interpret the results of systemic SKF83959 injections
in mice, which resulted in increased Ca21/calmodulin-
dependent protein kinase IIa phosphorylation and increased
brain-derived neurotrophic factor expression in striatal neu-
rons (Hasbi et al., 2009; Ng et al., 2010). It was also shown that
expression of glutamate decarboxylase-67 and the vesicular
glutamate transporters 1 and 2 in striatal neurons, when
injected into rats, was altered by SKF83959 (Perreault et al.,
2012b), which, again, was interpreted to be due to selective
D1-D2 heteromer activation.
In the current study, we further investigated the biology
and pharmacology of the proposed D1-D2 heteromer and the
mechanism of calcium mobilization in heterologous expres-
sion systems. Although we found that coactivation of both D1R
and D2R protomers is required for calcium mobilization to
occur, there appear to be multiple mechanisms besides Gq
activation through which this pathway is elicited. We also
studied the functional characteristics of SKF83959 to de-
termine its viability as a heteromer-selective in vivo ligand
and found that it was significantly less selective than
previously appreciated. In fact, we were not able to provide
evidence for selective activation of the D1-D2 heteromer.
These results indicate that D1Rs and D2Rs can synergize to
induce calcium mobilization, although the mechanisms of
activation are multiple and complex and there is not, as yet,
a selective pharmacology.
Materials and Methods
Human embryonic kidney 293-tsa201 (HEK293T) cells were a gift
from Dr. Vanitha Ramakrishnan. A D1R expressing stable cell line
was purchased from Codex Biosolutions, Inc. (Gaithersburg, MD).
[3H]N-methyl-(R)-(1)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-
tetrahydro-1H-3-benzazepine (SCH23390) (80.5 Ci/mmol) and [3H]N-
methylspiperone (85.5 Ci/mmol) were obtained from PerkinElmer
Life Sciences (Waltham, MA). Cell culture media and reagents were
purchased from MediaTech/Cellgro (Manassas, VA). Cell culture
flasks and materials and all assay plates were purchased from
Greiner Bio-One (Monroe, NC). SKF83959 and SKF83822 were
purchased from Tocris Bioscience/RD Systems (Minneapolis, MN).
All other compounds and buffer components were purchased from
Sigma-Aldrich (St. Louis, MO) except where indicated.
Cell Culture and Transfection. HEK293T cells and D1R CODEX
cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with a final concentration of 10% fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate,
and 10 mg/ml gentamicin. Cells were incubated at 37°C, 5% CO2,
and 90% humidity. They were passaged and plated mechanically
using calcium-free Earle’s balanced salt solution and pelleted by
centrifugation at 1000g for 10 minutes. For transfection studies,
HEK293T cells were seeded in 150-mm plates at 10  106 cells per
plate. After 24 hours, cells were transfected according to the
manufacturer’s recommendations using Clontech’s CalPhos trans-
fection kit (Clontech Laboratories, Inc., Mountain View, CA). The
DAR plasmid constructs were FLAG-tagged rat D1R, D2SR (D2 short
splice variant), or D2LR (D2 long splice variant) in the pCD-SRa vector
(Takebe et al., 1988; Monsma et al., 1990; Zhang et al., 1994) and D4R
in pcDNA3.1(1) vector (Schetz and Sibley, 2001). Additional experi-
ments were done using the Gq protein in the pcDNA3.1(1) vector
(Missouri S&T cDNA Resource Center, Rolla, MO) and various
functionally dominant negative G protein receptor kinase 2 (GRK2)
mutants: GRK2 C-terminus 495–689 in pcDNA3(1), GRK2 K220R in
pcDNA3(1), and empty pcDNA3.1(1) (Koch et al., 1994; Freedman
et al., 1995). For all transfections, 5 mg of each DNA construct was used
to transfect cells, with the exception of D1R, in which 10 mg was used.
Radioligand Binding Assays. Forty-eight hours after trans-
fection, cells were dissociated from plates using calcium-free Earle’s
balanced salt solution, and intact cells were collected by centrifuga-
tion at 900g for 10 minutes. Cells were resuspended and lysed using
5 mM Tris-HCl and 5 mM MgCl2 at pH 7.4 at 4°C. Cell lysate was
pelleted by centrifugation at 20,000g for 30 minutes and resuspended
in 5 mM Tris-HCl at pH 7.4; 100 ml of cell lysate (containing 8 mg of
protein for D2R assays or 10 mg of protein for D1R assays) was
incubated for 90 minutes at room temperature with various concen-
trations of [3H]N-methyl-SCH23390 (D1R binding) or [
3H]N-methyl-
spiperone (D2R binding) in a final reaction volume of 250 ml.
Nonspecific binding was determined in the presence of 4 mM (1)-buta-
clamol. Bound ligand was separated from the unbound by filtration
through a PerkinElmer Unifilter-96 GF/C 96-well microplate using
the PerkinElmer Unifilter-96 Harvester, washing three times, 1 ml
per well in ice-cold assay buffer. After drying, 50 ml of liquid
scintillation cocktail (MicroScint PS; PerkinElmer) was added to
each well, plates were sealed, and the plates were analyzed on
a PerkinElmer Topcount NXT. For competition binding assays, a fixed
concentration of 0.5 nM [3H]N-methyl-SCH23390 was incubated with
various concentrations of SKF83959, and the remainder of the assay
was performed as described already herein. Ki values were calculated
from observed IC50 values using the Cheng-Prusoff equation and a Kd
value of 0.5 nM for SCH23390, as determined in independent
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saturation isotherms (unpublished data). Expression of the D4R was
determined in an identical assay format as that for the D2R.
Competition Radioligand Binding Screen. A primary, single-
point radioligand competition binding assay was performed to assay
for radioligand binding inhibition by SKF83959 (10 mM). Forty-three
G protein–coupled receptors (GPCRs) and neurotransmitter-related
proteins were screened in the primary assay using radioligands with
known binding properties. The percentage of inhibition was calcu-
lated by subtracting the percentage of specific binding in the presence
of the test compound from the percentage of specific binding in the
absence of the test compound (n5 4). Receptors whose corresponding
radioligands had greater than 50% inhibition at 10 mM SKF83959
underwent secondary radioligand competition binding assays to
generate full competition curves. Ki determinations and receptor
binding profiles were provided by the National Institute of Mental
Health (NIMH) Psychoactive Drug Screening Program (PDSP),
Contract HHSN-271-2008-00025-C. The NIMH PDSP is directed by
Dr. Bryan L. Roth (University of North Carolina, Chapel Hill, NC) and
by Project Officer Jamie Driscol (NIMH, Bethesda, MD). For
experimental details, including radioligands used and associated Kd
values for each individual receptor, please refer to the PDSP website:
http://pdsp.med.unc.edu/.
Calcium Mobilization Assays. HEK293T cells were transiently
transfected as described; 24 hours after transfection, cells were plated
in 384-well, optical, clear-bottom, black-walled plates (20 ml/well,
30,000 cells/well; Greiner Bio-One). Forty-eight hours after trans-
fection, cells were incubated for 60 minutes at room temperature in the
dark with Fluo-8 NW calcium dye and an extracellular signal quencher
to block any signal from extracellular calcium (Screen Quest Fluo-8
NW Calcium Assay Kit; AAT Bioquest, Inc., Sunnyvale, CA), as
recommended by the manufacturer. The plates were then treated with
various concentrations of antagonist or agonists (diluted in the
presence of 0.2 mM sodium metabisulfite) as indicated in the Results
and figure legends. For agonist reads, plates were read kinetically in
real-time (every 0.6 second) by recording a baseline read for 14 seconds
before the addition of an agonist compound and then continually
measured for 2 minutes after agonist addition. For antagonist reads,
plates were read kinetically in real-time (every 0.6 second) by recording
a baseline reading for 20 seconds before the addition of that antagonist.
Then, 3 minutes later, agonist compound was added, and the plates
were read for an additional 3 minutes. All compound additions were
done in unison using the 384-tip onboard robotics on a Functional Drug
Screening System (FDSS) mCell (Hamamatsu, Bridgewater, NJ), and
plates were continuously read using the FDSS mCell from the bottom
throughout the assay with an excitation wavelength of 480 nm and an
emission wavelength of 540 nm. Data were recorded and quantified as
maximum minus minimum (max2min) relative fluorescence units
within the assay window using FDSS software. Data are expressed as
a percentage of the control max2min relative fluorescence units for
given studies as indicated in the figure legends. In these experiments,
D1R and D2R receptor expression levels typically varied between 1 and
3 pmol/mg protein. We found that coexpressing both receptors
sometimes affected their expression compared with expressing them
alone (unpublished data). However, this did not affect the calcium
mobilization response, which, although not studied in detail, appeared
to require simply a minimum level of dual receptor expression.
Statistical Analysis. Data are expressed as a percentage of
control values for individual experiments. Nonlinear regression of all
data was conducted on GraphPad Prism 5.01 (GraphPad Software,
Inc., La Jolla, CA). Results are expressed as mean 6 S.E.M.
See Supplemental Materials and Methods section for additional
procedures.
Results
Previous studies have suggested that the D1-D2 receptor
complex may signal as a heteromer and have implicated
SKF83959 as a compound that may selectively activate this
signaling complex (Lee et al., 2004; So et al., 2005; Rashid
et al., 2007a,b). However, these findings have not been
corroborated, and the mechanisms by which the D1-D2
receptor complex signals remain unclear. To investigate the
apparent ability of D1-D2 receptor oligomerization to alter the
G protein coupling of component receptors, we first tran-
siently expressed the D1R either alone or concurrently with
either the short (D2SR) or long (D2LR) isoforms of the D2R and
measured intracellular calcium mobilization via kinetic fluo-
rescence imaging. Preliminary coimmunoprecipitation experi-
ments revealed that D1-D2 hetero-oligomers were indeed
capable of forming under these expression conditions (Sup-
plemental Fig. 1). When cells were transfected with the D1R
and D2LR or the D1R with D2SR, a clear dose-dependent
activation of calciummobilization was observed in response to
DA (Fig. 1). Importantly, we observed no difference in coupling
efficacy or agonist potency between the short and long isoforms
of the D2R. However, when cells were transfected with any of
the subtypes alone, the receptors failed to couple to calcium
mobilization (Fig. 1). These data suggest that expression and
activation of both the D1R and D2R are essential for coupling to
calcium mobilization and signaling.
To investigate further that the activation of both receptor
subtypes is required to stimulate calcium mobilization, we
used receptor subtype–selective antagonists. Concentration
response inhibition curves for the D1R-selective (SCH23390)
and the D2R-selective (sulpiride) antagonists were generated
for cells transfected with the D1R and D2R (Fig. 2, A and B).
Cells were simultaneously stimulated with 1 mM DA and
examined for calcium mobilization. We observed complete
inhibition of the calcium signal with either SCH23390 or
sulpiride treatment. The potencies of the antagonists (SCH23390
IC50 ∼8.0 nM, sulpiride IC50 ∼0.7 nM) are consistent with their
known affinities for their selective subtypes as determined in
our laboratory (unpublished data) as well as by other groups
(Seeman and Van Tol, 1993; Millan et al., 2001). More
Fig. 1. Agonist-induced calcium mobilization in DA receptor–transfected
cells. HEK293T cells were transiently transfected with D1R, D2LR, D2SR,
D1R + D2LR, or D1R + D2SR, as indicated and described in Materials and
Methods. Twenty-four hours later, cells were plated in 384-well plates and
assayed the following day for calciummobilization after stimulation by DA
(D1R + D2LR EC50 = 73.8 nM, D1R + D2SR, EC50 = 58.2 nM). Data are
representative of three independent experiments done with the same
assay conditions on different days. Data are expressed as percentage of
control, normalized to the maximum signal seen via DA stimulation of
D1R + D2LR transfected cells. Error bars indicate S.E.M. from multiple
wells within the representative experiment.
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importantly, complete inhibition of the calcium response is
seen at antagonist concentrations that have no effect on the
opposite receptor subtype. Thus, selectively blocking DA
activation of either receptor subtype is sufficient to prevent
calcium mobilization, further suggesting that both receptor
protomers must be activated for this signaling to occur.
Whereas the studies using subtype-selective antagonists
suggested that both D1R and D2R are required for calcium
signaling, it might be possible that stabilizing one subtype
into an inactive state within a heteromer might alter the
conformation of the corresponding partner. Thus, to elucidate
further the coupling mechanism, subtype-selective agonists
were used to determine whether indeed activation of both
protomers is required for calciummobilization. As seen in Fig.
3, concurrent administration of a D1R-selective (SKF83822)
and a D2R-selective (quinpirole) agonist to cells cotransfected
with D1R and D2R resulted in a calciummobilization response
that nearly matched that of DA. In contrast, when D1R plus
D2R–cotransfected cells were stimulated with quinpirole
alone, no calcium mobilization was observed. Furthermore,
when the cotransfected cells were stimulated with SKF83822,
no calcium mobilization was seen at concentrations selective
for D1R. A small response was observed at 10 mM, but this was
at a concentration where SKF83822 loses receptor subtype
selectivity and can begin to stimulate the D2R as well.
Previous studies showed that SKF83822 has an affinity for
D1R in the ∼2 nM range and D2R in the ∼200 nM range
(O’Sullivan et al., 2004). Experiments done in our laboratory
have demonstrated a D2R affinity that is greater than 10 mM
(unpublished data), supporting the idea that the SKF83822-
mediated calcium response seen at high concentrations is due
to nonselective receptor activation. In addition, when cells
were transfected with any of the subtypes individually, no
signal was seen from any of the agonists (unpublished data).
Taken together, these data indicate that stimulation of both
receptor subtypes is necessary for calcium mobilization.
Previous studies suggested that SKF83959 may be a D1-D2
heteromer-selective compound, and a significant calcium
response to this ligand has been reported in cells coexpressing
the D1R and D2R (Lee et al., 2004; Rashid et al., 2007a,b;
Beaulieu and Gainetdinov, 2011). This compound has also
been reported to have seemingly paradoxical effects on the
D1R, exhibiting both antagonist and agonist properties,
depending on the system (Panchalingam and Undie, 2001;
Cools et al., 2002; Zhang et al., 2005). In our current studies,
we treated D1R and D2R cotransfected cells with SKF83959
and, surprisingly, were unable to elicit a calcium response
(Fig. 4A). Furthermore, when SKF83959 was added in concert
with the D2R selective agonist quinpirole, we were still unable
to observe a significant calcium response. It should be noted
that SKF83959 consistently failed to stimulate calcium mo-
bilization even when this experiment was performed using
different lots of compound from different vendors on separate
days, as well as with different drug solvents (unpublished
data). We also had one lot of compound chemically analyzed to
verify its purity (unpublished data). To demonstrate that the
SKF83959 compound was pharmacologically active in our
hands, we performed two separate experiments. As shown in
Fig. 4B, we stimulated calciummobilization with DA and then
Fig. 2. Inhibition of D1R + D2LR–mediated calciummobilization by either
D1R- or D2R-selective antagonists. HEK293T cells were transfected with
D1R + D2LR as described and 24 hours later were plated in 384-well plates.
Cells were incubated with the indicated concentrations of the D1R-
selective antagonist SCH23390 (A) or the D2R-selective antagonist sulpiride
(B) and then stimulated with an ∼EC80 of DA (1 mM; SCH23390 IC50 =
8.0 nM, sulpiride, IC50 = 0.7 nM). Data are expressed as a percentage of the
control (10 mM) DA response and are representative of two independent
experiments performed with the same assay conditions on different days.
Error bars indicate S.E.M. from multiple wells within the representative
experiment.
Fig. 3. Stimulation of D1R + D2LR–mediated calcium mobilization by
either D1R- or D2R-selective agonists. HEK293T cells were transfected
with D1 R+D2LR as described, plated 24 hours later in 384-well plates, and
assayed for calcium accumulation the following day. Cells were stimulated
with one of the following agonists as indicated: DA, the D1R-selective
agonist SKF83822, the D2R-selective agonist quinpirole, or both SKF83822
and quinpirole (D1R + D2LR EC50 = 610.8 nM) combined. Control cells
expressing the D1R, D2SR, or D2LR individually did not show a significant
calcium response to concurrent agonist administration. Data are expressed
as a percentage of control maximum DA-stimulated response and are
representative of two independent experiments performed with the same
assay conditions on different days. Error bars indicate S.E.M. from
multiple wells within the representative experiment.
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dose dependently added either the D1R-selective antagonist
SCH23390 as a control (see Fig. 2A) or SKF83959 to see
whether it might function as an antagonist in this system. In
fact, it did, exhibiting even higher potency than SCH23390,
although its efficacy of antagonism was less, exhibiting
a maximum inhibition of ∼50%. Finally, we performed a
radioligand binding competition assay with SKF83959 and
cells transfected with the D1R (Fig. 4C). SKF83959 was able
to compete potently and fully for radioligand binding to the
D1R. These experiments (Fig. 4, B and C) demonstrate that
SKF83959 is active in binding to the monomeric D1R, as well
as active as a partial antagonist of the calcium response
observed in D1R and D2R cotransfected cells. In contrast, it
does not appear to function as an agonist with respect to
stimulating calcium mobilization in the D1R and D2R cotrans-
fected cells.
Given the apparent discrepancies of our findings with some
previous studies (Lee et al., 2004; Rashid et al., 2007b; Hasbi
et al., 2011) and the possibility that SKF83959 may not be
as selective as previously thought, we sought to screen its
selectivity against various GPCRs. This was accomplished
through collaboration with the NIMH Psychoactive Drug-
Screening Program (http://pdsp.med.unc.edu). For the pri-
mary screen, a single-point radioligand binding competition
experiment was performed with 10 mM SKF83959 as a
competitor against an appropriate receptor-specific radio-
ligand of known properties. Forty-three GPCRs and signaling
proteins were screened this way, and 20 of them resulted in
.50% inhibition at 10 mMSKF83959 (Table 1). In contrast, 23
GPCR targets were found to have ,50% inhibition at 10 mM
SKF83959 and were therefore considered relatively “inactive/
low affinity” for SKF83959 (Supplemental Table 1). The 20
“active” receptors/proteins underwent secondary radioligand
competition binding experiments to generate full competition
curves for SKF83959 and Ki values for these receptors were
determined and are shown in Table 1. Of note is that the
serotonin 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, and 5-HT6
receptors; the adrenergic a2A, a2B, and a2C receptors; the
D1 D2, and D5 DARs; and the serotonin transporter all
have nanomolar Ki values. SKF83959 demonstrated very
high (sub-100 nM) affinity for four of these GPCRs: the
serotonergic receptor subtypes 5-HT2C, the adrenergic re-
ceptor subtype a2C, the D1, and D5 DAR subtypes, and the
serotonin transporter. Notably, SKF83959 has also recently
been shown to be a potent allosteric modulator of the s-1
receptor (Guo et al., 2013). Taken together, these data indicate
that SKF83959 has significantly high affinities for a wide
number of receptors and thus caution should be taken when
interpreting in vivo experimentation and the selectivity of
this agent.
Whereas D1 and D2 receptors appear capable of signal-
ing through calcium mobilization when both receptors are
Fig. 4. Pharmacological characterization of SKF83959 on D1R + D2LR–mediated calcium mobilization. HEK293T cells were transfected with D1R +
D2LR as described, plated 24 hours later in 384-well plates, and assayed for calcium accumulation the following day. (A) Cells were stimulated with one of
the following conditions as indicated: DA, SKF83959, the D2R-selective agonist quinpirole, or both SKF83959 and quinpirole combined. (B) Cells were
incubated with SKF83959 or the D1R-selective antagonist SCH23390, then stimulated with an ∼EC80 of DA (1 mM). Data are expressed as a percentage
of control maximumDA-stimulated response and are representative of two or three independent experiments performed with the same assay conditions
on different days. Error bars indicate S.E.M. from multiple wells within the representative experiment. (C) HEK293 cells stably transfected with D1R
(Codex Biosolutions, Inc., Gaithersburg, MD) were grown andmembranes harvested as described inMaterials andMethods. Membranes were incubated
with various concentrations of SKF83959 and 0.5 nM [3H]SCH23390 as indicated. Graph is representative of two independent experiments done on
different days. Data are expressed as specific binding in units of fmol/mg. Ki value was calculated using the Cheng-Prushoff equation and a radioligand
Kd value of 0.5 nM as determined via saturation binding isotherms (unpublished data). Average Ki for SKF83959 on D1R was 2.6 nM 6 0.7.
TABLE 1
SKF93959 competition binding experiments against various G protein–
coupled receptors
Ki values were derived from radioligand binding competition curves generated
against each of the above targets (n = 2) as described in Materials and Methods.






















a1A, a-adrenergic receptor subtype 1A; a1D, a-adrenergic receptor subtype 1D;
a2A, a-adrenergic receptor subtype 2A; a2B, a-adrenergic receptor subtype 2B; a2C,
a-adrenergic receptor subtype 2C; 5-HT1A, serotonergic receptor subtype 1A; 5-
HT2A, serotonergic receptor subtype 2A; 5-HT2B, serotonergic receptor subtype 2B;
5-HT2C, serotonergic receptor subtype 2C; 5-HT5A, serotonergic receptor subtype
5A; 5-HT6, serotonergic receptor subtype 6; M4, muscarinic receptor subtype 4; M5,
muscarinic receptor subtype 5; SERT, serotonin transporter.
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stimulated, the mechanism of transduction remains unclear.
To understand more clearly the mechanisms involved, we
tested the hypothesis that the receptors, perhaps within
the context of a heteromer, may switch G protein-coupling
selectivity and gain the ability to activate Gq. We first
examined this possibility by overexpressing Gqa in cells
expressing the D1R 1 D2R. Interestingly, the resulting DA-
stimulated calcium signal was increased by 200% compared
with cells transfected with the D1R 1 D2R alone (Fig. 5A).
Expression of only the Gqa protein in the absence of either
receptor did not enable the ability of DA to stimulate calcium
mobilization (Fig. 5A). In parallel studies, we examined how
overexpression of Gqa with the D1R or D2R alone could couple
to intracellular calcium mobilization. Consistent with Fig. 1,
cells transfected with D1R or D2R alone did not give a calcium
response. However, when Gqa was overexpressed, the D1R was
able to elicit a DA-stimulated calcium signal in the absence of
the D2R (Fig. 5B), although the calcium response was not as
large as that seen with the D1R 1 D2R 1 Gqa transfection (cf.
Fig. 5, A and B). No such phenomenon was observed with the
D2R. Taken together, these data suggest that the Gq protein
may be involved in calcium mobilization mediated by a D1-D2
heteromer, but this interpretation is complicated by the fact
that overexpression of Gqa can also lead to monomeric D1R
coupling.
Given our results with Gqa overexpression, we re-evaluated
SKF83959 stimulation of calcium mobilization under these
conditions in the D1R and D2R coexpressed cells. We found
that with Gqa overexpression, SKF83959 is able to stimulate
calcium mobilization in a manner similar to that of DA (Fig.
6A), whereas it is unable to stimulate such a response in cells
lacking Gqa overexpression (Figs. 4 and 6A). Interestingly,
SKF83959 was also able to stimulate calcium mobilization in
cells expressing the D1R and overexpressing Gqa, but not D1R
alone (Fig. 6A). These results led us to test the antagonist
sensitivity of the SKF83959 responses, as shown in Fig. 6B.
We found that the D1R-selective antagonist SCH23390 could
completely ablate SKF83959 stimulation of calcium mobili-
zation in both D1R 1 Gqa transfected and D1R 1 D2R 1 Gqa
transfected cells. However, in contrast to what we observed
for DA stimulation of D1R1 D2R cotransfected cells, the D2R-
selective antagonist sulpiride was unable to block SKF83959
stimulation of calcium mobilization. These results suggest
that overexpression of Gqa enables SKF83959 to stimulate
monomeric D1R present in the D1R and D2R cotransfected
cells, rather than enabling it to gain function as a D1-D2
heteromeric-selective agonist.
Although the extant hypothesis, which our overexpression
data support, is that Gq is central to the stimulation of calcium
mobilization, the central question is whether direct coupling
with a D1-D2 heteromer may be involved. An alternative
hypothesis is that the D1R and D2R signal through down-
stream pathways that converge on the Gq protein or other
components of the calcium mobilization process. To test
whether D1-D2 synergistic signaling is independent of Gi or
Gs protein function, we interfered with the activity of Gi and
Gs by treatment with toxins. D1R and D2R cotransfected cells
were incubated overnight in media containing pertussis toxin
(PTX) to inhibit Gi protein function (Namkung et al., 2009) or
cholera toxin (CTX) to interfere with Gs protein function
(Mannoury la Cour et al., 2011). Cells were then assayed for
calciummobilization in response to DA stimulation. We found
that treatment with CTX or PTX drastically, but not entirely,
reduced the calcium response (Fig. 7). These data support the
involvement of D1R-Gs– and D2R-Gi–mediated mechanisms
that majorly contribute to the calcium response in the D1R
and D2R cotransfected cells.
Another possibility, however, may be that general Gi-Gq
“cross-talk” is occurring after receptor activation, which leads
to PLC activation. Multiple cases of Gi-Gq cross-talk in other
receptor systems and cell types have been documented
(Okajima et al., 1989; Carroll et al., 1995; Toms and Roberts,
1999; Rebres et al., 2011), and Gi-Gq cross-talk in the D1-D2
receptor system could account for the PTX sensitivity of the
calcium signal. In this model, any Gi-linked GPCR, not just
the D2R, would be able to support a Gq-mediated calcium
response. To test this possibility, we used the D4R, a Gi-linked
DAR, which has not been found to form hetero-oligomers with
the D1R (González et al., 2012). We cotransfected the D1R and
D4R and compared the DA response with that in the D1R 1
D2R transfected cells (Fig. 8). In fact, the D4R did not support
a calcium response in the presence of coexpressed D1R,
Fig. 5. Influence of Gqa protein overexpression on D1R + D2LR–mediated
calcium mobilization. (A) HEK293T cells were transfected with D1R +
D2LR with and without Gqa or with Gqa alone (D1R + D2R EC50 = 168.3 nM,
ECmax = 100%; D1R + D2R + Gq EC50 = 16.8 nM, ECmax = 300.1%). (B)
HEK293T cells were transfected with D1R + D2LR, D1R, or D2R with and
without Gqa (D1R + Gq EC50 = 10.3 nM, ECmax = 152.2%). Twenty-four
hours later, cells were plated in 384-well plates and assayed the following
day for calcium mobilization after stimulation by the indicated concen-
trations of DA. Data are expressed as a percentage of control maximum
DA stimulation for D1R + D2LR alone and are representative of two or
three independent experiments performed with the same assay conditions
on different days. Error bars indicate S.E.M. from multiple wells within
the representative experiment.
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indicating that nonspecific Gi-Gq cross-talk, at least as pre-
viously described (Okajima et al., 1989; Carroll et al., 1995;
Toms and Roberts, 1999; Rebres et al., 2011). does not explain
the D1-D2 heteromer-mediated calcium response.
The potential involvement of multiple Ga-proteins led us to
also investigate other mechanisms by which D1R and D2R
activation could stimulate calcium mobilization. Notably, Gbg
subunits have been shown to increase cytoplasmic calcium
concentrations by stimulating PLCb (Beaulieu and Gainetdinov,
2011). A recent publication reported that the ghrelin receptor-
D2R dimer-linked calcium response was PTX sensitive, re-
quired PLC activity, and could be ablated by sequestering
the Gbg subunits (Kern et al., 2012). To see whether Gbg plays
a role in the D1-D2 heteromer-mediated calcium release, we
cotransfected the D1R and D2R with two different functionally
dominant negative GRK2 mutants. The mutants we used
were GRK2 K220R and the GRK2 C-terminal 495–689
peptide fragment (GRK2 c-term), both of which are unable
to phosphorylate GPCRs but can bind to and sequester Gbg
subunits (Koch et al., 1994; Freedman et al., 1995). We found
that overexpression of GRK2 K220R was able to ablate
completely DA-stimulated calcium mobilization in the D1R
andD2R cotransfected cells (Fig. 9A). Similarly, overexpression
of GRK2 c-term drastically reduced, but did not completely
ablate, the DA-stimulated calcium response (Fig. 7B). These
data suggest that the observed calcium mobilization occurring
in response to D1R and D2R activation is largely dependent on
free Gbg subunits.
Discussion
Receptor oligomers of many different GPCR types have
been proposed to form homo- or hetero-oligomers with
biochemical and functional characteristics that are unique
to their oligomeric conformations (Ferre et al., 2009). These
GPCR oligomers have been found not only to occur within
a type of GPCR but also across different classes, families,
types, and subtypes (Prinster et al., 2005). In addition to
signaling, internalization and degradation of GPCRs in homo-
and hetero-oligomers have been found to differ from their
monomeric activities (Milligan, 2004; Terrillon and Bouvier,
Fig. 6. SKF83959 stimulates D1R-dependent calciummobilization in the presence of Gqa. HEK293T cells were transfected with D1R + D2LR, Gqa or with
Gqa alone as described, plated 24 hours later in 384-well plates, and assayed for calcium accumulation the following day. (A) Cells were stimulated with
SKF83959. The line at 100% denotes the maximal DA response of D1R + D2LR cells. (B) Cells were incubated with the D1R-selective antagonist
SCH23390 (1 mM) or the D2R-selective antagonist sulpiride (1 mM) and then stimulated with an∼EC80 of SKF83959 (100 nM). Error bars indicate S.E.M.
from multiple wells within the representative experiment, which was replicated twice with similar results. DMSO, dimethylsulfoxide.
Fig. 7. G protein dependency of D1R + D2LR–mediated calcium
mobilization. HEK293T cells were transfected with D1R + D2LR. Cells
were incubated overnight in 1 mg/ml PTX or 1 mg/ml CTX; 48 hours post
transfection, cells were assayed for calcium mobilization by stimulation
with the indicated concentrations of DA (CTX ECmax = 14%, inhibition =
86% control, PTX ECmax = 24%, inhibition = 76% control). Data are
expressed as a percentage of control maximum DA stimulation seen in
untreated D1R + D2LR cells and are representative of two or three
independent experiments performed with the same assay conditions on
different days. Error bars indicate S.E.M. from multiple wells within the
representative experiment.
Fig. 8. Dopamine does not elicit a calcium response in cells co-expressing
the D1R and D4R. HEK293T cells were transiently transfected with D1R +
D2LR or D1R + D4R, as indicated and described in Materials and Methods.
Twenty-four hours later, cells were plated in 384-well plates and assayed
for calcium mobilization through stimulation by the indicated concen-
trations of DA. Data are expressed as a percentage of control maximum
DA stimulation seen in cells transfected with D1R + D2LR only (EC50 =
162.0 nM) and are representative of two or three independent experiments
done with the same assay conditions on different days. Expression of the
D4R was confirmed using radioligand binding assays as described in
Materials and Methods and was similar to that of the D2R. Error bars
indicate S.E.M. frommultiple wells within the representative experiment.
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2004; Prinster et al., 2005; Ferre et al., 2009; Missale et al.,
2010). Like previously described receptor oligomers, it has
been shown that the D1R and D2R can coimmunoprecipitate
with each other (Lee et al., 2004; Pei et al., 2010; Supplemen-
tal Fig. 1), and fluorescence imaging has shown that the two
receptors cointernalize when one or the other receptor is
stimulated (O’Dowd et al., 2005, 2012; So et al., 2005; Dziedzicka-
Wasylewska et al., 2006; Łukasiewicz et al., 2009). We have
demonstrated that the calcium response is unique to cells that
coexpress both D1 and D2 DARs and that the DARs must be
costimulated, as an antagonist to either receptor blocks the
transduction. However, the mechanism of action and whether
heteromers or homomers form the functional units for calcium
signaling remain unclear.
It has been suggested that the coactivation of the D1-D2
complex causes a conformational change that results in the
direct interaction between the C terminus of the D1R and the
third intracellular loop (ICL3) of the D2R (O’Dowd et al.,
2012). The ICL3 is the only region of difference between D2LR
and D2SR, and there is evidence that it results in differences
in the G protein coupling and signaling capabilities of each
D2R isoform (Kendall and Senogles, 2011). Recently, it was
proposed that the ICL3 of D2LR, but not the D2SR, could form
a complex with the D1R (Pei et al., 2010), but the findings
were based on the use of glutathione S-transferase and trans-
activator of transcription–fused D2R ICL3 fragments, which
may not accurately mimic native receptor conformations and
interactions. Later, it was shown that both D2R splice isoforms
were able to cointernalize with the D1R (O’Dowd et al., 2012).
Our results show that both D2SR and D2LR can couple with the
D1R to mobilize calcium (Fig. 1), and we have found that this is
also true for both human (unpublished data) and rat DARs. We
have also confirmed that both receptors must be expressed in
the same cell and coactivated to induce a calcium response in
HEK293T cells.
Our data also suggest that Gq protein signaling may play
a role in the calcium response elicited by the D1-D2 complex.
This was demonstrated by observing increased calcium
mobilization in response to DA in cells transfected with the
D1R and D2R plus Gqa. However, we also observed that the
D1R alone may couple to Gqa when the a subunit is expressed
in significantly high amounts. This is likely due to the D1R
having a relatively low affinity for Gqa; however, it may
activate Gq-mediated calcium mobilization under conditions
where Gq expression is very high. This is also supported by the
enhanced calcium response we observed when the D1R and
D2R are coexpressed in the presence of high levels of Gq
protein, where the D1R is the protomer within the heteromer
that likely activates Gqa (Rashid et al., 2007b). In this model,
it is hypothesized that the D2R allosterically modulates the
D1R (Rashid et al., 2007b; Hasbi et al., 2011). We believe,
however, that the enhanced calcium mobilization seen in the
D1R 1 D2R 1 Gqa transfected cells is not due solely to D1R
monomer activation of Gq, as the degree of calcium mobiliza-
tion (300% of control, Fig. 5A) is twice that seen in the D1R-
Gqa transfected cells (Fig. 5B). Interestingly, another study
has also reported D1R-mediated calcium release from internal
stores in mouse cells lacking thymidine kinase transfected
with the human D1R (Liu et al., 1992), indicating that this is
not an event particular to our experimental paradigm. Thus,
although Gq may play a role in the apparent ability of the
D1-D2 heteromer to couple to calcium signaling, this role may
be dependent on the level of Gq protein expression, either on a
total cellular basis, which would thus be cell-type dependent,
or this signaling may be localized to specific membrane mi-
crodomains (see discussion to follow).
It has also been suggested that SKF83959 may act as a
D1-D2 heteromer-selective agonist, and it has been used as
a putative heteromer-selective probe in vivo. However, these
studies are not without controversy, as SKF83959 has
a history of unusual pharmacology. Panchalingam and Undie
(2001) found that SKF83959 inhibited D1R-stimulated cAMP
formation and also induced striatal intracellular calcium
mobilization in rats and monkeys. It lacked the side effects
typical to D1R agonists that stimulate cAMP production but
paradoxically seemed to cause typical D1R agonist-like
behaviors in rats (Perreault et al., 2010) and is an effective
anti-Parkinsonian agent inMPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydrapyridine)-lesioned monkeys unresponsive to L-Dopa
(L-3,4,-dihydroxyphenylaline) (Andringa et al., 1999). In our
hands SKF83959 did not stimulate a calcium response in cells
Fig. 9. GRK2 influence on DA-mediated D1R + D2LR calcium mobiliza-
tion. HEK293T cells were transiently transfected with D1R + D2LR and
either empty pcDNA vector the GRK2 catalytically inactive mutant GRK2
K220R (A) (D1R + D2R EC50 = 269.1 nM) or the GRK2 C-terminal 495–689
fragment (B; GRK2 c-term; D1R + D2R EC50 = 90.4 nM, ECmax = 100%
control; D1R+D2R + pcDNA EC50 = 188.5 nM, ECmax = 106%; D1R + D2R +
GRK2 c-term EC50 = 288.1 nM, ECmax = 30% control, 70% inhibition), as
indicated and described in Materials and Methods. Twenty-four hours
later, cells were plated in 384-well plates and assayed the following day
for calcium mobilization after stimulation by the indicated concentrations
of DA. Data are expressed as a percentage of control maximum DA
stimulation seen in cells transfected with D1R + D2LR only and are
representative of two or three independent experiments done with the
same assay conditions on different days. Error bars indicate S.E.M. from
multiple wells within the representative experiment.
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transfected with both the D1R and D2R, despite the fact that
it was active in binding to the D1R. In fact, it appeared to act
as an antagonist of the DA-stimulated calcium response in
D1R and D2R cotransfected cells. In contrast, when Gqa was
overexpressed, SKF83959 stimulated a calcium response in
cells cotransfected with the D1R and Gqa, as well as cells
cotransfected with D1R, D2R, and Gqa. However, we observed
that whereas the D1R-selective antagonist SCH23390 com-
pletely blocked the SKF83959-stimulated calcium response in
both transfection conditions, the D2R-selective antagonist
sulpiride was ineffective in the D1R and D2R cotransfection
condition. This contrasts with sulpiride’s ability to block
completely DA-stimulated calcium mobilization in the D1R
and D2R cotransfected cells (cf. Figs. 2B and 6B). This finding
suggests that SKF83959 is not activating the D1-D2 hetero-
mer but rather is activating only D1R monomers that exist in
the D1R and D2R cotransfected cells. This could be explained
by the functionally selective or biased agonist properties of
SKF83959 in that it can selectively activate D1R-Gq signaling,
provided there is sufficient Gqa present, but our current
results do not support its ability to activate the D1-D2
heteromer.
It has also been proposed that D1-D2 heteromer activation
via SKF83959 in vivo and in vitro results in increased
Ca21/calmodulin-dependent protein kinase IIa levels in
the striatum and nucleus accumbens, further resulting in
enhanced brain-derived neurotrophic factor expression and
increased neuronal maturation and differentiation (Rashid
et al., 2007a; Hasbi et al., 2009; Ng et al., 2010; Perreault
et al., 2012b). Given that our experiments indicated that
SKF83959 could not induce D1-D2 heteromer–selective
calcium mobilization in a controlled cell environment, we
conducted a single-point competition-binding screen against
an array of 43 GPCRs and additional signaling proteins
(Supplemental Table 1; Table 1). We observed that SKF83959
demonstrated considerably high affinity for multiple recep-
tors and other signaling proteins, and we conducted second-
ary competition binding experiments on the ones for which it
showed the highest affinity. Surprisingly, SKF83959 showed
nanomolar affinities for many different GPCRs, including
several serotonergic, adrenergic, dopaminergic, and musca-
rinic receptor subtypes (Table 1). This result, as well as our
functional data, questions whether SKF83959 may be useful
as a selective probe to study D1-D2 heteromer or even D1-like
receptor signaling in vivo.
Our data also suggest that calcium signaling through the
D1-D2 receptor complex is largely sensitive to Gi and Gs
inhibition by PTX and CTX, respectively. This led us to
investigate additional hypotheses for the mechanism of D1-D2
calcium signaling. Recently, Kern et al. (2012) showed that
the ghrelin receptor could hetero-oligomerize with the D2R.
This heteromer induced calcium release from internal cellular
stores in a PLC-dependent and PTX-sensitive manner and
seemed to require Gbg subunit activation. Previous studies
have shown that GRK2 can bind to and sequester Gbg
subunits (Koch et al., 1994), and catalytically inactive GRK2
mutants that retain Gbg binding have been used as tools
to block Gbg signaling without the complication of added
Fig. 10. Various mechanisms of PLCb activation that may occur when the D1R and D2R are coexpressed and coactivated.
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receptor desensitization (Koch et al., 1994; Freedman et al.,
1995). Our data demonstrated that the catalytically inactive
GRK2 K220R mutant completely ablated the DA-stimulated
calcium response in the D1R and D2R transfected cells, whereas
GRK2 c-term (a truncated GRK2 protein that includes only
the Gbg binding domain) largely decreased the calcium re-
sponse. Since activated Gbg subunits can stimulate PLCb
activity (Camps et al., 1992), our results are consistent with
the hypothesis that the DA-stimulated calcium response
significantly involves Gbg activation of PLCb. Additionally,
the N-terminal RGS domain of GRK2 has been shown to
facilitate weak GTPase-activating protein-like activity on Gq,
inhibiting PLC activation. This may explain the difference in
degree of calcium signal inhibition between the GRK2 K220R
mutant and the truncated GRK2 c-term mutant (Carman
et al., 1999). Therefore, the activation of PLCbmay be Gqa- as
well as Gbg-dependent and due largely to synergistic cross-
talk between the D1R and D2R.
Figure 10 represents several hypothetical signaling path-
ways for D1-D2 receptor-calcium signaling in HEK293T cells.
Pathway A represents D1-D2 heterodimer activation of Gq
leading to Gqa activation of PLCb, as has been hypothesized in
the literature (Rashid et al., 2007b). Pathway B represents
Gbg activation of PLCb, where free b/g subunits could arise
through activation of either Gs, Gi, or Gq. Pathway C
represents coactivation of D1R and D2R monomers and
cross-talk between Gs and Gi protein–mediated downstream
signaling pathways, ultimately leading to PLCb activation.
Given that PTX and CTX can nearly eliminate the DA-
stimulated calcium signaling, we believe that pathway A is
largely inoperative in our system under basal conditions.
Pathway C could readily account for the requirement for dual
receptor activation, but the fact that Gbg sequestration largely
eliminates the DA calcium response suggests that pathway
B is critically important. The PTX/CTX results further
implicate Gs or Gi; however, the requirement for dual receptor
activation in pathway B is not completely clear. Certainly,
additional work is required to answer these questions, but
it is clear from these studies that D1-D2 receptors can
dually activate calcium signaling through more than a single
mechanism.
One additional consideration for D1-D2-calcium signaling,
which does not necessarily exclude the possibility of hetero-
mer formation, may involve the aggregation of the two DARs
and their associated proteins in lipid rafts. Lipid rafts are
a well-known but poorly understood platform for modulating
certain protein-protein interactions in neurons as well as
affecting GPCR ligand sensitivity, membrane trafficking, and
signaling (Allen et al., 2007; Korade and Kenworthy, 2008;
Björk and Svenningsson, 2011; Kong et al., 2011; Sebastião
et al., 2011; Celver et al., 2012). Lipid rafts would readily
enable cross-talk between the D1R and D2R and could assist
in the multifaceted signaling profile of the D1-D2 receptor
complex. In addition, differences in lipid raft composition, cell
background, and assay detection may explain some of the
differences observed between our data and the data generated
by other groups. Despite the seeming complexity of the D1-D2
receptor signaling mechanisms, it may yet be useful to study
how synergistic concurrent activation of the D1R and D2Rmay
induce effects not seen when either receptor is expressed
alone. This can be examined by coexpressing mutants of the
the D1R and D2R, which have been reported to be unable to
form dimers (O’Dowd et al., 2012), and studying the effect of
coactivation on the generation of a calcium signal. Addition-
ally, a compound that can selectively bias both receptors
toward a conformation that promotes PLC activation may be
useful in providing a clearer understanding of the DAR
system in vivo.
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